James P. Catania

A rigorous cost-benefit assessment can help to chart a cost-effective path forward.

Executive management leadership is essential in the effective implementation of QbD.

By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.